Capricor Therapeutics (NASDAQ:CAPR) Shares Gap Down – What’s Next?

Capricor Therapeutics, Inc. (NASDAQ:CAPR) gapped down prior to trading on Friday . The stock had previously closed at $30.40, but opened at $27.20. Capricor Therapeutics shares last traded at $26.1710, with a volume of 432,139 shares traded.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on CAPR. Piper Sandler reissued an “overweight” rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Cantor Fitzgerald set a $62.00 price objective on shares of Capricor Therapeutics and gave the company an “overweight” rating in a report on Friday, March 13th. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Capricor Therapeutics in a research report on Wednesday, May 13th. Finally, B. Riley Financial upped their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research report on Friday, March 13th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.30.

Capricor Therapeutics Stock Performance

The firm has a fifty day simple moving average of $30.18 and a 200 day simple moving average of $28.43. The company has a market capitalization of $1.53 billion, a PE ratio of -11.45 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Research analysts expect that Capricor Therapeutics, Inc. will post -0.75 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction that occurred on Tuesday, March 31st. The shares were sold at an average price of $30.13, for a total transaction of $753,250.00. Following the transaction, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $247,758.99. This trade represents a 75.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Karimah Es Sabar sold 61,265 shares of the business’s stock in a transaction that occurred on Tuesday, March 31st. The stock was sold at an average price of $30.17, for a total transaction of $1,848,365.05. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 173,429 shares of company stock worth $5,329,440. Insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in Capricor Therapeutics by 16.1% during the fourth quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after purchasing an additional 355,161 shares in the last quarter. Suvretta Capital Management LLC bought a new position in Capricor Therapeutics in the fourth quarter worth about $51,533,000. Tang Capital Management LLC bought a new position in Capricor Therapeutics in the fourth quarter worth about $49,062,000. RA Capital Management L.P. purchased a new stake in shares of Capricor Therapeutics during the fourth quarter valued at about $43,516,000. Finally, Geode Capital Management LLC lifted its position in shares of Capricor Therapeutics by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock valued at $29,367,000 after buying an additional 55,766 shares during the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.